Avid Bioservices Inc (CDMO)

[biopharm]

I wouldn't really call it out for nothing as any Sumitomo ties of a company could easily spend some cash and as Cramer told us ...it can be "fun"

I wonder if Brian Weston at Ronin Capital with John Springs Stafford could give the go ahead on algo change and make this more interesting

Interesting ties that Sumitomo has...actually, Peregrine collaborator or Avid/Oncologie collaborator Biothera with CMO Dr Jose Iglesias just so happens to be with Boston Biomedical and the puzzle pieces are alive and kicking

Why is John Springs Stafford so quiet? He used to enjoy sending out shareholder letters

Dr Iglesias needs better glasses to see the 3D live images of a drugs MOA to see what happens first....unless he has a personal conflict, and RPG can use an MD that remains quiet

Maybe one of these days they surprise us

_________

Welcome Dr. José Iglesias to ResearchPoint Global as Medical Director, Oncology.
We are pleased to announce that Dr. José Iglesias has joined ResearchPoint Global, a WuXi AppTec company as Medical Director, Oncology. Dr. Iglesias will serve as the expert in all new oncology programs and assist in the development of a proactive oncology strategy that will open doors and attract sponsors seeking a CRO with extensive oncology expertise.

“We are very fortunate to have attracted José as our own internal oncology expert,” says Alfonso Alanis, RPG’s Chief Medical Officer. “I have known José for over twenty years, and he is a very gifted scientist. José is well known and well respected in the field of clinical oncology globally and has a broad network which includes some of the principal thought leaders in modern oncology. He has worked with some of the most traditional oncology platforms as well as the most novel ones including immuno-oncology and genomics.”

Throughout his 28-year career in the pharmaceutical industry, Dr. Iglesias exhibited his scientific expertise while occupying global senior leadership positions at Apobiologix, Biothera, Bionomics, Celgene, Abraxis BioScience, Amgen Canada, and Eli Lilly. Dr. Iglesias has designed and led all phases of oncology clinical trials, as well as authored or co-authored more than 60 publications in the field of oncology. In his most recent role as Vice President of Medical and Clinical Affairs, he furthered the development of oncology biosimilars at Apobiologix.

“I am delighted to join the dynamic RPG team,” says Dr. Iglesias. “I look forward to helping PRG build up a solid oncology strategy and assisting it in becoming a preferred partner in oncology clinical development. RPG’s approach is unique in the CRO industry and has great potential to be very successful in furthering the progress of oncology clinical research worldwide.”

Dr. Iglesias will attend the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 to June 5. He would be pleased to liaise and network with investigators, organizations, and institutions interested in moving forward their Oncology clinical development projects. To set an appointment with Dr. Iglesias, please contact him at [e-mail], or at his mobile phone, [phone].

https://www.researchpointglobal.com/rpg-welcomes-jose-iglesias-oncology/

_____

Let's go Dr Iglesias ....what activates what? : )

Developer of a cancer immunotherapy platform technology intended to improve immune health. The company's cancer immunotherapy platform technology works as an immunological ignition switch to activate a host of anti-tumor immune system responses that enhance the therapeutic efficacy of immune checkpoint inhibitors and other monoclonal antibodies, enabling cancer patients to begin treatment quickly, resulting in a higher likelihood of a successful treatment.

https://pitchbook.com/profiles/company/84208-69

Targeting flipped PS is that activation that THEN allows the rogue protein pathways to get those protein pathways moving